AG
TRVI icon

Algert Global’s Trevi Therapeutics TRVI Stock Holding History

Algert Global’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,779
Closed -$61K – 1328
2024
Q4 		$61K Sell
14,779
-9,810
-40% -$31.4K ﹤0.01% 1139
2024
Q3 		$82K Buy
+24,589
New +$73.1K ﹤0.01% 1129

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Algert Global's TRVI Position: Q1 2025 in Review

Algert Global sold out of Trevi Therapeutics (TRVI) in Q1 2025, closing a stake of 14,779 shares — an estimated $61K sold.

Algert Global first reported a position in TRVI in Q3 2024 and held it in 2 quarters. The position peaked at $82K in Q3 2024. 137 funds tracked by Wall St. Rank hold TRVI as of Q1 2025.

  • Algert Global reported no remaining Trevi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Algert Global sold 14,779 Trevi Therapeutics shares in Q1 2025, an estimated $61K.
  • Algert Global first reported a position in Trevi Therapeutics in Q3 2024 and held it in 2 quarters.
  • Algert Global's Trevi Therapeutics position peaked at $82K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2025.

Based on Algert Global's 13F filing for Q1 2025, filed 13 May 2025.